Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.62 |
| ▸ | CA2 | P00918 | 9/20 | 0.62 |
| ▸ | CA9 | Q16790 | 7/20 | 0.62 |
| ▸ | CA12 | O43570 | 6/20 | 0.62 |
| ▸ | CA4 | P22748 | 3/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583348 | 0.85 | PDE4B (0.69) | CA1CA2CA9CA12CA4 | |
| SCHEMBL499992 | 0.85 | PDE4B (0.69) | CA1CA2CA9CA12CA4 | |
| SCHEMBL596577 | 0.82 | CA1 (0.56) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13470651 | 0.82 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19851265 | 0.81 | CA1 (0.58) | CA1CA2CA9CA12CA4 | |
| SCHEMBL13470643 | 0.80 | CA1 (0.53) | CA1CA2CA9CA12CA4 | |
| SCHEMBL20936503 | 0.79 | CA1 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL12521418 | 0.78 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1135328 | 0.78 | CA1 (0.65) | CA1CA2CA9CA12CA4 | |
| SCHEMBL12875294 | 0.77 | CA1 (0.78) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226057-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | TOLREMO THERAPEUTICS AG (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230137869-A1 | METHOD OF SUGAR-GUIDED MODIFYING GLYCOSYLATED POLYPEPTIDE AND APPLICATION OF THE SAME | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2023-05-04 | — | — | US | disclosed |
| US-20230137869-A1 | METHOD OF SUGAR-GUIDED MODIFYING GLYCOSYLATED POLYPEPTIDE AND APPLICATION OF THE SAME | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2023-05-04 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021108683-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021064142-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| US-10874679-B2 | Boron-containing small molecules | BILL & MELINDA GATES FOUNDATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200230160-A1 | BORON-CONTAINING SMALL MOLECULES | BILL AND MELINDA GATES FOUNDATION (US) | 2020-07-23 | — | — | US | disclosed |
| WO-2020114499-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-06-11 | — | — | WO | disclosed |
| EP-2343304-A1 | Biocidal boronophthalide compounds | Anacor Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7767657-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| CN-1068005-C | Oxaboroles and salts thereof, and thire use as biocides | ZENECA LTD (GB) | 2001-07-04 | — | — | CN | disclosed |
| EP-0765331-B1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | AVECIA LTD (GB) | 2000-08-09 | — | — | EP | disclosed |
| US-5880188-A | PROTECTING MEDIUM SUSCEPTIBLE TO MICROBIAL ATTACK BY TREATING WITH SPECIFIED OXABOROLE COMPOUND | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| CN-1155286-A | Oxaboroles and salts thereof, and thire use as biocides | ZENECA LTD (GB) | 1997-07-23 | — | — | CN | disclosed |
| EP-0765331-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033754-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200230160-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BTD | CA1 3591/4885CA2 743/4885CA9 380/4885 |
| US-10874679-B2 | Boron-containing small molecules | BCL6B, BLVRB, BTD | CA1 3591/4885CA2 743/4885CA9 380/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885CA9 980/4885 |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885CA9 980/4885 |
| US-20230226057-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | CPT1A, SLC10A1, FGF1 | CA1 2894/4885CA2 1442/4885CA9 1616/4885 |
| US-20230137869-A1 | METHOD OF SUGAR-GUIDED MODIFYING GLYCOSYLATED POLYPEPTIDE AND APPLICATION OF THE SAME | DNPEP, FUT6, MGAM | CA1 1039/4885CA2 1792/4885CA9 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.